Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling

NCT01538771 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Myocardial Infarction

Interventions

DRUG: Darbepoetin alfa
DRUG: Control Saline

Sponsor

Seoul National University Bundang Hospital